ICS/LABA Adherence and COPD Exacerbation

AstraZeneca

Status: Completed

Conditions: Chronic Obstructive; Pulmonary Disease

Treatments: Other: Non-Interventional Study

Study type: Observational

Funder types: Other; Industry

Identifiers

NCT02446041

D589BR00034

Details and patient eligibility

About

The purpose of this retrospective, non-interventional sutdy is to compare the effectiveness of ICS/LABA combination therapy in the reduction of COPD exacerbations during the 12 months after initiation of therapy between COPD patients who are adherent to the index medication and those who are non-adherent.

Full description

This retrospective, observational study will assess the effectiveness of ICS/LABA combination therapies among COPD patients new to the ICS/LABA combination therapies in the US, comparing those who are adherent to the index medication and those who are non-adherent. Adherence will be measured using the proportion of days covered with the index medication. Medical and pharmacy claims data will be used as the data source.

Enrollment: 10,000 patients

Sex: All

Ages: 40 to 99 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• at least one prescription fill for ICS/LABA combination during identification period.
• COPD diagnosis
• 40 years or older at index date
• > or = 12 months of continuous health plan enrollment prior to and following index date
• 1 or more prescription for SABA, SAMA or SABA/SAMA during the pre-index period.

Exclusion criteria

• Patients with prescription claim for ICS/LABA combination therapy during the 12 month pre-index period
• Patients receiving oral corticosteroid medication for more than 180 days during the 12 month pre-index period
• Patients with cancer diagnosis in 12 month pre-index period

Trial design

10,000 participants in 1 patient group

ICS/LABA Patients

Description:

ICS/LABA Patients following standard of care

Treatment:

Other: Non-Interventional Study